<DOC>
	<DOCNO>NCT01726348</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness darunavir treatment human immunodeficiency virus-type I ( HIV-1 ) infection among Filipino adult .</brief_summary>
	<brief_title>A Study Assess Safety Effectiveness Darunavir Treating Human Immunodeficiency Virus-Type I ( HIV-1 ) Infection Filipino Patients</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center ( study conduct multiple site ) , uncontrolled ( patient receive darunavir ) clinical observational study ( study investigators/physicians observe patient measure outcome ) evaluate safety effectiveness darunavir treatment human immunodeficiency virus-type 1 ( HIV-1 ) infection among adult Filipino patient . The study enroll 10 percentage patient would use product , requirement Philippine Food Drug Administration ( FDA ) . Patients monitor baseline every 4 week thereafter period 24 week . Safety evaluation adverse event , clinical laboratory test , physical examination , concomitant medication , co-morbid condition monitor throughout study . The duration treatment 24 week total study conduct 3 year .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Patients diagnose human immunodeficiency virustype 1 ( HIV1 ) , eligible darunavir ( combination ritonavir ) treatment . These may either : treatmentnaive adult patient treatmentexperienced adult patient darunavir resistance associate substitution ; treatmentexperienced adult patient least one darunavir resistance associate substitution Known hypersensitivity darunavir/ritonavir component two agent preparation Pregnant breastfeeding female Agrees protocoldefined use effective contraception Patients take medication highly dependent Cytochrome P450 3A4 clearance initial concentration associate serious and/or life threaten event Patients severe hepatic impairment History allergy sulfa contain drug molecule Patients currently receive alfuzosin , dihydroergotamine , ergonovine , ergotamine , methylergonavine , cisapride , pimozide , midazolam , triazolam , St. John 's Wort ( Hypericum perforatum ) , lovastatin , simvastatin , rifampin sildenafil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Human Immunodeficiency Virus-Type 1</keyword>
	<keyword>HIV-1</keyword>
	<keyword>TMC114</keyword>
	<keyword>Darunavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Filipino</keyword>
</DOC>